• Determine the capacity of your therapeutic to bind to components of whole blood with an in vitro cell binding assay
  • Whole blood procured from local IRB-approved blood centers
  • The following cell subsets may be assessed, from the same or different donors:
    • Red blood cells
    • Platelets
    • PBMCs freshly isolated from whole blood
  • Assess cell binding via fluorescence detection of a directly-conjugated therapeutic or an appropriately selected fluorescent secondary antibody
  • Strict positive and negative controls are included for each cell subset of interest, along with various concentrations of your therapeutic
  • Data are provided in appropriate formats, including PowerPoint slides, Excel files, and/or direct data files (e.g., GraphPad Prism)

Service Overview

About the Whole Blood Cell Binding Assay

Off-target binding of a therapeutic molecule to cellular components of whole blood can be a safety concern in the clinic. For example, drug interactions with platelets can cause platelet activation and destruction, thereby increasing the risk for thrombocytopenia, a low platelet count. Off-target binding of a therapeutic to cellular components in the blood may also affect biodistribution and bioavailability of that therapeutic, ultimately impacting its pharmacokinetic properties. The whole blood cell binding assay provides an in vitro screen to determine the binding potential of a therapeutic to cell types of interest (off-target or on-target) using flow cytometric analysis.

At iQ Biosciences, we have experience performing cell binding assays with all cellular components of whole blood. In this assay, fresh whole blood is obtained from healthy donors and processed into multiple components: red blood cells (RBCs), platelet rich plasma (PRP), and/or peripheral blood mononuclear cells (PBMCs; T cells, B cells, monocytes, and natural killer cells). Cells are incubated with the therapeutic candidate, followed by and appropriate fluorescently-labeled secondary antibody, if applicable, in order to detect test article binding to each target cell type. Cells are co-stained with appropriate lineage markers, as applicable, to identify potential therapeutic binding to cell subsets of interest within PBMCs. This assay is typically performed with a range of therapeutic concentrations and with more than one healthy donor to elucidate any dose-responsive or donor-dependent effects.

The iQ Experience

Tailored Experiments

Your research is important to us. Our scientists will work through each step of the process with you, including assay design, data analysis, and recommendations for future studies.

Streamlined Process

Simplify your workflow. Bypass the middle-man: at iQ Biosciences, you'll get immediate access to our biospecimen inventory, saving you both valuable time and money.


We're experts- so you don't have to be. Augmenting years of experience in immunology and working with immune assays, our scientists stay current with the latest publications and technology.

Exceptional Service

We're here to help. We know the challenges you're facing: whether it be through expedited service or our complimentary consulting services, our team is dedicated to helping you reach your goals.

Order Information


At iQ Biosciences, we understand that each client is unique. Upon quote request, we will provide complimentary consulting services to determine how to tailor our services to best meet your goals. Based on this preliminary assessment, we will be able to provide a price quote.

Expected Timetable

Fit a timetable appropriate to your research goals. We work with you to determine your expected turn-around on a case-by-case basis and ensure that our services fit your needs. Some experiments may require an expedited service – please inquire for more information.